Kornimate/medical-research-clean huggingface dataset:
prevalence of eosinophilic esophagitis in children with celiac disease

Conditions: Celiac Disease; Eosinophilic Esophagitis

Summary: celiac disease (cd) and eosinophilic esophagitis (ee) are distinct diseases of the gastrointestinal tract with specific clinico-pathological characteristics. in recent years, in the literature, several children who underwent upper gastrointestinal endoscopy for suspected cd, which was confirmed histologically, were also found to have coexistent ee. there are reports of coexistent cd and ee. we would like to see the prevalence of ee in children with cd and the prevalence of cd in children with ee in our population, and to do so would like to review medical records. our objectives are to determine if children with celiac disease have a high prevalence of eosinophilic esophagitis.and to determine if children with eosinophilic esophagitis have increased risk of developing celiac disease.


Eligibility criteria:
inclusion criteria: * seen in the pediatric gastroenterology clinic at st. john hospital \& medical center during study time frame * age 2-21 years old * diagnosed with cd or ee or both based on the endoscopic and histopathological findings . exclusion criteria: * gastroesophageal reflux diagnosed by ph probe. * history of chemical ingestion
developing a real-time pcr assay for fusobacterium and epidemiological analysis of tumor patients

Conditions: Fusobacterium Infections

Summary: this study presents an academic approach to developing a fluorescence quantitative pcr detection method capable of accurately measuring the presence of fusobacterium (specifically f. nucleatum, f. mortiferium, f. varium, f. ulcerans, f. and f. necrogens) in human fecal samples. it aims to perform an epidemiological analysis on the presence of fusobacterium in patients with tumors, elucidating the prevalence of fusobacterium members in this patient population. additionally, it seeks to investigate the potential correlation between fusobacterium presence and various test indicators, diagnostic predictions, and prognosis outcomes.

fusobacterium nucleatum, a gram-negative obligate anaerobic bacterium, is known to colonize the oral cavity and is implicated in various diseases affecting the oropharynx, gastrointestinal tract, cardiovascular vessels, and genital tract. precise classification of the fusobacterium genus is of utmost importance as it will facilitate a deeper understanding of the pathogenicity of its members in tumor development, establish an accurate etiological association with tumors, and ultimately enhance clinical practice and epidemiological investigations.

Eligibility criteria:
inclusion criteria: * the inclusion criteria for this study encompassed fecal specimens obtained from patients with a documented history of tumor, specifically those who received their primary or initial tumor diagnosis at our hospital. * inclusion criteria for the control group consisted of the following: (1) individuals who were in good health, devoid of evident diseases, and possessed normal physical examination reports; (2) individuals who had not experienced significant chronic illnesses, such as hypertension, diabetes, chronic kidney disease, etc., in recent years, in order to exclude those who had been unwell but had normal physical examination reports; (3) age and gender were matched with the case group. exclusion criteria: the exclusion criteria for this study include: a) individuals who have taken an antimicrobial preparation within the past three months. b) samples that lack complete information and cannot be traced back to their source. c) samples with an insufficient volume for detection. d) samples that do not meet the requirements for sample collection and preservation. -

Keywords: fusobacterium pcr
translational approaches to septic cardiomyopathy

Conditions: Cardiomyopathies; Sepsis; Septic Shock

Summary: this translational study will assess the association between septic cardiomyopathy (measured via left ventricular global longitudinal strain) and (a) inflammatory cytokine profiles, and (b) the behavior of cardiomyocytes derived from inducible pluripotent stem cells.


Eligibility criteria:
inclusion criteria at least 18 years of age admitted to the icu sepsis patients: sepsis patients must have: 1. suspected or confirmed infection and 2. organ dysfunction as defined by a sofa \>= 2 above baseline (if no baseline data available, sofa assumed to be 0) or septic shock patients: after infusion of 20ml/kg crystalloid or equivalent, septic shock patients must have: 1. suspected or confirmed infection and 2. lactate \> 2 mmol/l and 3. receiving vasopressors exclusion criteria known pregnancy primary diagnosis of acute coronary syndrome known preexisting heart disease known severe valvular disease (regurgitation or stenosis) major cardiac dysrhythmia such as: * ventricular tachycardia (v-tach) * ventricular fibrillation (v-fib) * third degree heart block (complete hear block or complete av block)

Keywords: septic cardiomyopathy cytokine ipsc inducible pluripotent stem cell
machine learning approach based on echocardiographic data to improve prediction of cardiovascular events in hypertrophic cardiomyopathy

Conditions: Hypertrophic Cardiomyopathy

Summary: hypertrophic cardiomyopathy is a pathology with a highly variable course, ranging from patients who are asymptomatic throughout their lives to those who experience sudden death and/or terminal heart failure. the main objective is to develop and validate an algorithm (constructed through supervised learning) using cardiac imaging data to predict the risk of cardiovascular events in sarcomeric hypertrophic cardiomyopathy.


Eligibility criteria:
inclusion criteria: * age \>18 * patients with confirmed sarcomeric hypertrophic cardiomyopathy exclusion criteria: * echocardiographic data not allowing deep analysis (technical default, bad echogenicity of the patient) * other causes of left ventricular hypertrophy that may hamper the diagnosis (p.e. aortic or sub-aortic stenosis, severe renal insufficiency, hypertension). * history of ischemic heart disease or associated myocarditis * opposition of the patient to the use of his/her data
meso-car t cells therapy for relapsed and refractory ovarian cancer

Conditions: Ovarian Cancer

Summary: the goal of this clinical trial is to study the feasibility and efficacy of anti-meso antigen receptors (cars) t cell therapy for relapsed and refractory ovarian cancer.

primary objectives 1.to determine the feasibility ad safety of anti-meso car-t cells in treating patients with meso-positive ovarian cancer. secondary objectives 1. to access the efficacy of anti-meso car-t cells in patients with ovarian cancer. 2. to determine in vivo dynamics and persistency of anti- meso car-t cells.

Eligibility criteria:
inclusion criteria: 1. 18 to 70 years old, female; 2. expected survival \> 12 weeks; 3. clinical performance status of ecog score 0-2; 4. patients who have previously been treated with second- line or more lines of standard treatment are not effective (no remission or recurrence after remission); 5. at least one measurable tumor foci according to recist standard 1.1 ; 6. positive mesothelin expression in tumor tissues; 7. creatinine ≤ 1.5×uln; 8. alt and ast ≤ 3×uln; 9. total bilirubin ≤ 2×uln; 10. hemoglobin≥90g/l; 11. absolute counting of neutrophils≥1000ul ; 12. absolute counting of lymphocytes\>0.7×10\^9/l; 13. counting of platelet≥75000/ul; 14. the venous access required for collection can be established without contraindications for leukocyte collection; 15. able to understand and sign the informed consent document. exclusion criteria: 1. accompanied by other uncontrolled malignant tumors; 2. active hepatitis b, hepatitis c, syphilis, hiv infection; 3. suffering severe cardiovascular or respiratory disease; 4. any other diseases could affect the outcome of this trial; 5. any affairs could affect the safety of the subjects or outcome of this trial; 6. pregnant or lactating women, or patients who plan to be pregnancy during or after treatment; 7. there are active or uncontrollable infections (except simple urinary tract infections or upper respiratory tract infections) that require systemic therapy 14 days or 14 days prior to assignment; 8. patients who are accounted by researchers to be not appropriate for this test; 9. received car-t treatment or other gene therapies before assignment; 10. subject suffering disease affects the understanding of informed consent or comply with study protocol.

Keywords: car-t meso ovarian cancer relapsed and refractory
potential impact of the use of the application ventilo after cardiac surgery

Conditions: Mechanical Ventilation Complication

Summary: mechanical ventilation is a vital support associated with the treatment of patients with acute respiratory failure and in other indications such as surgery under general anesthesia, coma or shock. optimization of settings during mechanical ventilation and implementation of protective ventilation help to avoid ventilation-induced injury, ensure adequate oxygenation and maintain adequate carbon dioxide concentration to avoid respiratory acidosis or alkalosis. similarly, there is also no clear recommendation, to our knowledge, for the initial setting of the respiratory rate. therefore, initial settings are not always adequate and in the literature the frequency of respiratory acidosis is very high, reaching about half of the patients receiving mechanical ventilation. ventilo, is an application that is available on smart phones. this educational application provides clinicians with initial settings and optimization of these settings based on gender, height, weight, body temperature and patient type. the algorithm used is based on published data regarding ventilatory requirements in different populations and the anatomical and instrumental dead space of patients. the purpose of our study is to: assess whether ventilatory settings after intensive care unit admission after cardiac surgery are appropriate to compare the ventilatory adjustments made by clinicians with those proposed by the ventilo application.


Eligibility criteria:
inclusion criteria: * adults (\> or = 18 years old) * intubated patients admitted to the icu immediately postoperative from cardiac surgery * obtained a postoperative arterial gas within 1 hour of arrival in the icu exclusion criteria: * lack of patient anthropometric data (height and weight) available in the patient record
emotional attention bias modification and targeted memory reactivation in alcohol use disorder

Conditions: Alcohol Use Disorder

Summary: through this protocol, researchers examine whether targeted memory reactivation (tmr), a technique used to enhance memory, can augment the control of craving levels in patients with alcohol use disorder by enhancing positive emotional attention bias modification.

this protocol uses tmr during rem sleep to strengthen associative memories generated by emotional attention bias modification (eabm), an effective treatment for controlling craving levels in patients with alcohol use disorder (aud). eabm involves exposure to negative emotional words (e.g., frustrated, inferior) associated with alcohol-related cues and positive emotional words (e.g., successful, confident) associated with healthy lifestyle cues. the goal is to reduce alcohol-related cue positive emotional attention bias (eabs). in eabm training, alcohol-related cues and healthy activity (e.g., exercising, reading, playing musical instruments) images are always paired with negative words and positive words, respectively. the tmr group receives the eabm protocol with auditory cue feedback (sound s1-alcohol; sound s2-healthy life); the control group receives the eabm protocol without auditory cue feedback. all patients will perform eabm every evening and will be exposed to sounds s1 and s2 during rem sleep with a wireless headband, which automatically detects sleep stages. clinical evaluation of the eab and craving levels of aud will be conducted before and after (with a 2-week follow-up). the investigators hypothesize that patients treated with eabm and who are exposed during rem sleep to a sound that had previously been associated with the new negative memory of alcohol and the positive memory of a healthy lifestyle (tmr group) will have more reduced eab and craving levels compared to participants exposed to the same, but non-associated, sound during rem sleep (control group).

Eligibility criteria:
inclusion criteria: * aged 18-55 years; meets the diagnostic criteria for alcohol use disorder according to the diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) (american psychiatric association, 2013); alcohol withdrawal period of less than 6 months; normal vision and hearing, or corrected to normal; agrees to participate in the study and is able to cooperate to complete the experiment. exclusion criteria: * acute alcohol withdrawal period: clinical institute withdrawal assessment for alcohol scale (ciwa-ar) score ≥ 9; history of organic brain diseases or brain trauma; history of seizures, other neuropsychiatric disorders, or family history of psychiatric disorders; presence of substance abuse/addiction other than alcohol (excluding nicotine addiction).
acceptability of active monitoring (am) as a treatment option for ductal carcinoma in situ (dcis)

Conditions: Ductal Carcinoma in Situ

Summary: the purpose of this research study is to evaluate a decision support tool for patients diagnosed with ductal carcinoma in situ (dcis).

today, guideline concordant care options for patients diagnosed with ductal carcinoma in situ (dcis) are lumpectomy (with or without radiation treatment) and mastectomy, with optional endocrine therapy. several ongoing trials are evaluating the safety of active monitoring (am) as an alternative to immediate surgery for select patient groups. little is known about women's acceptability of am after a diagnosis with dcis. here the study team seeks to answer the question: if am is found to be a safe alternative to immediate surgery, how likely are women to choose it as their first course of treatment? in this study, women are asked to imagine having recently been diagnosed with dcis. for some in the intervention arm, in-depth information about surgical options and am are presented with a web-based decision support tool. after exploring the decision support tool, participants are asked to make a hypothetical treatment choice and to answer a series of additional questions about their decision-making process and personal preferences. women in the control arm receive a reduced version of the decision support tool that only provides in-depth information about the surgical options (am is mentioned as an experimental approach). the overarching hypothesis of this study is that patients who are offered am as a guideline-concordant care option (a potential future scenario if ongoing trials confirm the safety of am) are more likely to choose it compared to women in current clinical practice (who receive information about surgical options only). primary research question: compared to presenting active monitoring (am) as an experimental option, does presenting am as a guideline-concordant care option increase its uptake as treatment choice? secondary research questions: compared to presenting active monitoring (am) as an experimental option, does presenting active monitoring as a guideline-concordant care option increase am acceptability, decrease perceived am riskiness, and decrease uptake of mastectomy as treatment choice?

Eligibility criteria:
inclusion criteria: * sex: female * age: 50-79 years * has had a negative mammographic screen in the past 12 months exclusion criteria: * personal history of breast cancer

Keywords: ductal carcinoma in situ decision support tool informed decision-making overtreatment active surveillance active monitoring
nanomotion-based resistell ast to determine the antibiotic susceptibility of gram-negative bacteria causing bacteremia and/or sepsis

Conditions: Bacteremia Sepsis

Summary: blood culture samples from bacteremia patients positive for gram-negative bacteria will be tested for antibacterial susceptibility using resistell phenotech device. the results will be compared with current ast gold standard tests to calculate sensitivity, specificity, and accuracy of resistell phenotech device.

nano-rast: nano-motion based resistell ast to determine the antibiotic susceptibility of bacteria causing bacteremia and sepsis. study population: patients admitted at the study site with bacteremia considered to be due to a pathogenic strain (e. coli or k. pneumoniae). study design: prospective, observational, single arm study.

Eligibility criteria:
inclusion criteria: the patients meeting all the following criteria can be recruited in the study: * patients over the age of 18 years who sign, or their relatives / legal representatives sign the informed consent form; * patients with bacteremia considered to be due to a pathogenic strain; * patients hospitalized at chuv at the time of blood culture inoculation; * patients whose positive blood cultures were not older than 24 hours at the time of ast start. exclusion criteria the patients meeting any of the following criteria will be excluded from the study: * patient is diagnosed with polymicrobial bacteremia; * samples can be excluded from the study during the processing of samples in case of technical errors e.g. failure with attachment of cells, technical problem with the device or sensor, operator's error, etc. note: in the event that the capacity of the resistell instruments is reached for the day, no more icfs will be obtained for the day.

Keywords: bacteremia sepsis antibiotic susceptibility testing ast gram-negative resistell phenotech nanomotion cantilever
block reducing pain after surgery trial

Conditions: Chronic Pain Post-Procedural

Summary: this observational study evaluates difference in chronic pain after six months from surgery between patients who received pecs block and general anesthesia versus general anesthesia alone.

pecs block is used as a pain relief technique during breast surgery. however at the actual state of knowledge there is no strong evidence that its use could lower incidence of chronic pain compared to general anesthesia alone. moreover for its use an adequate skill with ultrasound machine is required. for this reason only some anesthesiologists in our reality use this technique it in clinical practice.

Eligibility criteria:
inclusion criteria: * programmed breast surgery * informed consent exclusion criteria: * bilateral breast surgery

Keywords: anesthesia, regional ;pecs block
safety and efficacy study of bondease to treat traumatic lacerations and surgical incisions

Conditions: Traumatic Lacerations or Surgical Incisions

Summary: to demonstrate that bondease™ and conventional wound closure devices (cwcd) are the same in terms of cosmesis (appearance) of the repaired wound when these devices are used for closure of surgical and traumatic wounds . to demonstrate safety of bondease™.

this is a two-phase, multi-center, prospective, randomized, parallel-group study, in which a total of 153 subjects (102 in the bondease™ group and 51 in the cwcd group) with traumatic lacerations and incisions will be enrolled. overall, eligible subjects will be randomized in a pre-defined 2:1 ratio to bondease™ skin adhesive or cwcd. in part 1 of the study 30 subjects will be randomized in a 2:1 ratio (bondease™ : cwcd). this part of the study is designed to assess the feasibility and validate use of the device. pediatric subjects younger than age 18 will not be included in this part of the trial. the results from these 30 subjects will be compiled and submitted to fda for review and approval prior to proceeding with part 2. part 2 of the study will only be initiated after fda indicates it is acceptable to begin. in part 2 of the study a total of 123 subjects will be randomized, of which 82 subjects will be randomized to the bondease™ group and 41 subjects to the cwcd group. this will result in 102 subjects in the bondease™ group and 51 subjects in the cwcd group across the both parts of the trial.

Eligibility criteria:
inclusion criteria: 1. male and female subjects at least 1 year of age (for part 2 only) or at least 18 years of age (for both part 1 and part 2). 2. has a wound requiring surgical repair, where the use of a tissue adhesive is appropriate 3. is in good general health 4. subject or the guardian understands and is willing to sign informed consent prior to study entry and agrees to be available for the day 10, day 28, and day 90 (part 1/pilot phase only) follow-up visits exclusion criteria: 1. significant or multiple traumas 2. known peripheral vascular disease 3. known diabetes mellitus type 1 or type 2 4. known blood clotting disorder 5. patient or family history of keloid formation or hypertrophy 6. known hiv seropositivity or is immunocompromised 7. been treated with an investigational drug or medical device in the past 30 days 8. a hypersensitivity or contraindication to any of the components of bondease™ 9. known pre-operative systemic or local infection 10. any other diseases or conditions which might interfere with the wound healing process 11. the wound to be treated with the test device may not have any of the following characteristics: * a "burst" or stellate laceration * heavily contaminated (contaminated wound: wounds that are grossly contaminated with foreign material requiring extensive cleansing. * human or animal bite * decubitus etiology * evidence of active infection or gangrene * on mucosal surfaces or across mucocutaneous junctions (e.g., oral cavity, lips) * on an area which may be regularly exposed to body fluids or with dense natural hair, (e.g., scalp) * under tension or over a joint